title: Different potencies of angiotensin receptor blockers at suppressing adrenal β-Arrestin1-dependent post-myocardial infarction hyperaldosteronism.
authors.forename: Anastasios
authors.initials: A
authors.lastname: Lymperopoulos
authors.forename: Emmanuel
authors.initials: E
authors.lastname: Sturchler
authors.forename: Ashley
authors.initials: A
authors.lastname: Bathgate-Siryk
authors.forename: Samalia
authors.initials: S
authors.lastname: Dabul
authors.forename: Dilayda
authors.initials: D
authors.lastname: Garcia
authors.forename: Karlee
authors.initials: K
authors.lastname: Walklett
authors.forename: Giuseppe
authors.initials: G
authors.lastname: Rengo
authors.forename: Patricia
authors.initials: P
authors.lastname: McDonald
authors.forename: Walter J
authors.initials: WJ
authors.lastname: Koch
mesh_terms: D000450:Aldosterone / Q000097:blood; D047228:Angiotensin II Type 1 Receptor Blockers / Q000627:therapeutic use*; D000818:Animals; D001562:Benzimidazoles / Q000627:therapeutic use*; D001713:Biphenyl Compounds; D006929:Hyperaldosteronism / Q000517:prevention & control*; D009203:Myocardial Infarction / Q000150:complications*; D051381:Rats; D013777:Tetrazoles / Q000627:therapeutic use*; D014633:Valine / Q000031:analogs & derivatives* / Q000627:therapeutic use; D000068756:Valsartan
chemical_list: D047228:Angiotensin II Type 1 Receptor Blockers; D001562:Benzimidazoles; D001713:Biphenyl Compounds; D013777:Tetrazoles; D000450:Aldosterone; D000068756:Valsartan; D014633:Valine; C081643:candesartan